CompletedInterventional · Phase 1/2NCT05757570 ↗Open-Label Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Povetacicept in Subjects With Autoimmune Cytopenias (RUBY-4)Maria Teresa DeSanchoPIInterventionDrug: PovetaciceptDatesJul 2023 – Aug 2026
CompletedInterventional · Not applicableNCT05759013 ↗A Randomized, Sham Controlled, Double-blinded, Multi-center Trial to Evaluate the Efficacy of the VentFree Respiratory Muscle Stimulator to Assist Ventilator Weaning in Critically Ill PatientsLisa K TorresPIInterventionDevice: Breath synchronized abdominal FES · Device: Sham breath synchronized abdominal FESDatesFeb 2024 – Feb 2026SponsorLiberate Medical LLCRespiration, ArtificialVentilators, Mechanical
CompletedInterventional · Phase 4NCT05767749 ↗Characterizing and Comparing the Duration of Local Anesthetic in Dermatologic SurgeryKira MinkisPILisa M KernPIInterventionDrug: lidocaine + epinephrine 1:100,000 · Drug: Ropivacaine 0.5% Injectable Solution · Drug: Bupivacaine 0.5% Injectable SolutionDatesMar 2023 – Jul 2023· Results postedSponsorWeill Medical College of Cornell UniversityAnesthetics, Local
CompletedInterventional · Phase 2/3NCT05769582 ↗Safety, Tolerability and Efficacy of AntiBKV as Treatment of BKV Infection in Kidney Transplant Recipients, a Randomized Phase II/III Study, Double-blind and Placebo-controlledDarshana M DadhaniaPIInterventionBiological: Anti-BK polyomavirus (AntiBKV)DatesApr 2023 – Mar 2025SponsorMemo Therapeutics AGBK ViremiaBKV DNAemia
TerminatedInterventional · Phase 1NCT05787496 ↗A Phase 1, Open-Label, Safety, Tolerability, And Efficacy Study of NC525 in Subjects With Advanced Myeloid NeoplasmsPinkal DesaiPIInterventionDrug: NC525DatesFeb 2023 – Jan 2025· Results postedSponsorNextCure, Inc.Relapsed or Refractory Acute Myeloid LeukemiaRelapsed or Refractory Chronic Myelomonocytic LeukemiaRelapsed or Refractory Myelodysplastic Syndrome
CompletedInterventional · Phase 4NCT05796557 ↗ECMO Hemostatic Transfusions in ChildrenMarianne Elizabeth NellisPIInterventionBiological: Platelet TransfusionDatesDec 2023 – Jan 2025· Results postedSponsorYale UniversityExtracorporeal Membrane Oxygenation ComplicationHemorrhageThromboembolism+1 more
CompletedInterventional · Phase 2NCT05819359 ↗A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson's Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) GeneHarini SarvaPIInterventionDrug: BIA 28-6156 10 mg · Drug: BIA 28-6156 60 mg · Drug: PlaceboDatesMar 2023 – Apr 2026SponsorBIAL R&D Investments S.A.Parkinson's Disease
CompletedInterventional · Phase 4NCT05822583 ↗Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy TrialMatthew William McCarthyPIAlexander DrelickPIInterventionDrug: abatacept infusion · Drug: Placebo groupDatesJul 2023 – Jun 2025· Results postedSponsorUniversity of MinnesotaCOVID-19
CompletedInterventional · Phase 3NCT05822830 ↗A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide in Adults Who Have Obesity or Overweight With Weight Related ComorbiditiesAlpana P. ShuklaPIInterventionDrug: Tirzepatide · Drug: SemaglutideDatesApr 2023 – Nov 2024· Results postedSponsorEli Lilly and CompanyObesityOverweight
TerminatedInterventional · Not applicableNCT05823922 ↗Feasibility and Efficacy of Mobile Cognitive Behavioral Therapy for Medical and Graduate StudentsPatricia MarinoPIInterventionBehavioral: Clinician Delivered CBT · Behavioral: Supplemental MAYA AppDatesNov 2023 – Nov 2024SponsorWeill Medical College of Cornell UniversityAnxiety DisordersDepression
CompletedInterventional · Phase 3NCT05882045 ↗A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular DiseaseLouis J AronnePIInterventionDrug: Retatrutide · Drug: PlaceboDatesMay 2023 – Apr 2026SponsorEli Lilly and CompanyObesityCardiovascular Diseases
CompletedInterventional · Not applicableNCT05890872 ↗A Clinical Study of Aliya™ Pulsed Electric Fields (PEF) Delivered Prior to Standard of Care Treatment for Advanced CancerBradley B PuaPIInterventionDevice: Aliya Pulsed Electric Fields (PEF)DatesSep 2023 – Aug 2025SponsorGalvanize Therapeutics, Inc.Lung Neoplasm Malignant
CompletedInterventional · Not applicableNCT05900037 ↗A Prospective, Multicenter, Randomized Clinical Investigation Evaluating GATT-Patch for Hemostasis During Minimally Invasive Liver and Gallbladder SurgeryBenjamin SamsteinPIInterventionDevice: GATT-Patch · Device: SURGICEL® OriginalDatesOct 2023 – Jul 2025SponsorGATT Technologies B.V.Intraoperative BleedingLiver DiseasesGallbladder Diseases+1 more
CompletedInterventional · Phase 2NCT05921903 ↗A Phase 2b, Randomized, Controlled, Open-label Study to Evaluate the Immune Response and Safety of the RSVPreF3 OA Investigational Vaccine in Adults (>=18 Years of Age) When Administered to Lung and Renal Transplant Recipients Comparing 1 Versus 2 Doses and Compared to Healthy Controls (>=50 Years of Age) Receiving 1 Dose.Catherine Butkus SmallPIInterventionBiological: RSVPreF3 OA Investigational VaccineDatesJul 2023 – Jun 2024· Results postedSponsorGSK Research & Development LimitedRespiratory Syncytial Virus Infections
CompletedInterventional · Phase 1NCT05924243 ↗A Phase 1b, Adaptive, Multi-Center, Randomized, Double Blind, Placebo-Controlled, Parallel Design Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's DiseaseHarini SarvaPIInterventionDrug: RO7486967 · Drug: PlaceboDatesSep 2022 – Jul 2024SponsorF. Hoffman La-Roche LtdParkinson Disease
TerminatedInterventional · Phase 2NCT06005610 ↗Giving Standardized Estradiol Therapy In Transgender Women to Research Interactions With HIV TherapyCarrie JohnstonPIInterventionDrug: EstradiolDatesJan 2024 – Aug 2025· Results postedSponsorNational Institute of Allergy & Infectious DiseasesHIV I Infection
CompletedInterventional · Phase 2NCT06006247 ↗A Randomized, Double-Blind, Placebo-Controlled Trial of CVN424 in Early Parkinson's DiseaseHarini SarvaPIInterventionDrug: CVN424 150 mg · Drug: PlaceboDatesSep 2023 – Jan 2025· Results postedSponsorCerevance Beta, Inc.Parkinson's Disease
TerminatedInterventional · Phase 1NCT06034860 ↗A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer TypesAnna C PavlickPIInterventionDrug: MT-8421 · Drug: NivolumabDatesNov 2023 – Oct 2024SponsorMolecular Templates, Inc.Non Small Cell Lung CancerHepatocellular CarcinomaMelanoma+8 more
CompletedInterventional · Phase 2NCT06055985 ↗A Multicenter Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's DiseaseHarini SarvaPIInterventionOther: Placebo · Drug: UCB0022DatesNov 2023 – Mar 2025SponsorUCB Biopharma SRLParkinson Disease
CompletedInterventional · Phase 3NCT06060665 ↗IDEAL: A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)Sonal KumarPIIlan Seth WeisbergPIInterventionDrug: Seladelpar 10 mg · Drug: PlaceboDatesSep 2023 – May 2026SponsorCymaBay Therapeutics, Inc.Primary Biliary Cholangitis